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The echinocandins are the newest class of antifungal agents in the clinical armory. These secondary
metabolites are non-competitive inhibitors of the synthesis of b-(1,3)-glucan, a major structural compo-
nent of the fungal cell wall. Recent work has shown that spontaneous mutations can arise in two hot spot
regions of Fks1 the target protein of echinocandins that reduce the enzyme’s sensitivity to the drug. How-
ever, other strains have been isolated in which the sequence of FKS1 is unaltered yet the fungus has
decreased sensitivity to echinocandins. In addition it has been shown that echinocandin-treatment can
induce cell wall salvage mechanisms that result in the compensatory upregulation of chitin synthesis
in the cell wall. This salvage mechanism strengthens cell walls damaged by exposure to echinocandins.
Therefore, fungal resistance to echinocandins can arise due to the selection of either stable mutational or
reversible physiological alterations that decrease susceptibility to these antifungal agents.
 2009 Elsevier Inc.Open access under CC BY license.1. Introduction
The fungal cell wall perhaps represents the ideal target for the
therapeutic treatment of fungal pathogens of humans. The vast
majority of the mass of the cell wall of all fungi is comprised of car-
bohydrate polymers that are completely absent from the human
body. In most fungi, two covalently cross-linked polysaccharides,
b-(1,3)-glucan and chitin, form a primary cell wall skeleton that
is responsible for structural integrity and shape of the cell (Latge,
2007). This skeletal layer in the inner wall is often surrounded by
further polysaccharides composed of mannose, galactose and other
sugars that may be covalently attached to cell wall proteins. The
complete absence of any one of these glycan polymers is usually
lethal to fungal pathogens. Consequently, the enzymes of fungal
cell wall polysaccharide biosynthesis are highly speciﬁc and poten-
tially cidal targets for antifungal secondary metabolites and anti-
fungal drugs.
Despite the promise of the cell wall as an antifungal target, few
classes of cell wall inhibitors have been successfully developed for
clinical use. The notable exception is the echinocandins that were
discovered in the 1970s by random screening of secondary metab-
olites. These are cyclic hexapeptides modiﬁed with lipid side
chains that are essential for their antifungal activity. Caspofungin
was the ﬁrst echinocandin to be approved for clinical use by the
FDA followed by anidulafungin and micafungin. The drugs are
administered by IV injection and have a relatively broad spectrum
of activity with cidal action against most Candida species, and
either fungicidal or fungistatic action against Aspergillus fumigatus).
Y license.(Denning, 2003). They are less effective against Cryptococcus
neoformans, Fusarium and Scedosporium although they are able to
inhibit growth of Pneumocystis (Perlin, 2007). The echinocandins
bind to Fks1, a sub-unit of b-(1,3)-glucan synthase, but their bind-
ing is non-competitive (Douglas et al., 1997) and formal proof that
Fks1 is the catalytic b-(1,3)-glucan synthase is still lacking.
In fungi, the integrity of the b-(1,3)-glucan–chitin cell wall scaf-
fold is monitored and regulated constantly to ensure cell viability.
This is not a trivial challenge since surface expansion during
growth and cellular morphogenesis requires a delicate balance to
be maintained between the rigidity and the ﬂexibility of the cell
wall. This balance between plasticity and rigidiﬁcation must also
be achievable in the presence of lytic enzymes or antibiotics, such
as the echinocandins, that may compromise the integrity of the cell
wall. Disruption of genes in cell wall biosynthetic pathways of
Saccharomyces cerevisiae and Candida albicans often results in alter-
ation and redistribution of chitin and b-(1,3)-glucan in the cell
wall, synthesis of new wall proteins and changes in the cross-link-
ing to alternative wall polysaccharides (see below). Defects in cell
wall integrity are sensed by transmembrane proteins such as Mid2
and theWsc family leading to activation of the Rho1 GTPase and its
downstream targets including protein kinase C and the b-(1,3)-glu-
can synthase sub-units ScFks1 and ScFks2 (Levin, 2005). In S. cere-
visiae, C. albicans and presumably other fungi this ‘‘cell wall
salvage” or ‘‘cell wall compensatory” mechanism is activated in re-
sponse to wall-perturbing agents such as Calcoﬂuor White (CFW),
Congo Red, caffeine and b-glucanases. The response is mediated
primarily through the protein kinase C (PKC) cell integrity mito-
gen-activated protein (MAP) kinase cascade and its downstream
target the transcription factor ScRlm1 (Bermejo et al., 2008; Boor-
sma et al., 2004; Garcia et al., 2004, 2009; Kuranda et al., 2006;
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larity glycerol response (HOG) pathway, has also been suggested to
play a role in regulating cell wall architecture (Bermejo et al., 2008;
Garcia-Rodriguez et al., 2000, 2005) (Fig. 1). Finally the Ca2+–calci-
neurin pathway has also been implicated in the activation of cell
wall biosynthetic processes in response to damage of the cell wall
(Fig. 1) (Lagorce et al., 2003; Walker et al., 2008).
2. FKS1 hot spot mutations confer echinocandin resistance
Global surveillance studies have reported that there is no evi-
dence of any trends towards echinocandin-resistance emerging
within clinical isolates of Candida species (Pfaller et al., 2006a,b).
However, there are a growing number of reports of breakthrough
infections in patients receiving echinocandin therapy (Table 1).
The mechanism behind the resistance of the clinical isolates
responsible for many of these breakthrough infections was ﬁrst
elucidated by in vitro studies (Park et al., 2005). Point mutations
within the FKS1 target gene were identiﬁed in C. albicans strains
that were less susceptible to caspofungin after exposure to the
drug. Point mutations were then identiﬁed in resistant clinical iso-
lates and were clustered around two hot spot regions of the FKS1
gene (Park et al., 2005; Perlin, 2007). The mutation hot spots
map onto amino acids at positions 641–649 (hot spot 1) and
1345–1365 (hot spot 2) of C. albicans Fks1. Point mutations within
these regions are common to a number of different resistant C. albi-
cans clinical isolates with substitution of the serine at position 645
to phenylalanine, proline or tyrosine being the most frequently ob-Sensors
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et al., 2005). Garcia-Effron et al., 2009b evaluated the MICs of iso-
lates harboring mutated Fks1 enzymes and found a link between
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In S. cerevisiae there is an alternative glucan synthase catalytic
sub-unit ScFks2/Gsc2 that is expressed in response to mating pher-
omone, sporulation and starvation conditions (Mazur et al., 1995).
ScFKS2 is induced by calcium in a calcineurin dependent manner
(Mazur et al., 1995). A third related protein ScFks3 has a role in
spore wall assembly (Ishihara et al., 2007). Orthologous proteins
are present in other fungal genomes so most fungi contain more
than one glucan synthase catalytic sub-unit. Fks1 and its orthologs
seem to be the key players during vegetative growth and are the
main targets of the echinocandins (discussed below). However, a
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as Candida guilliermondii and Candida glabrata that resulted in an
elevated echinocandin MIC (Garcia-Effron et al., 2009a; Katiyar
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Fig. 2. Treatment of fungal cells with caspofungin. Transmission electron micro-
graphs of Candida albicans yeast cells grown in YPD medium at 30 C for 6 h in the
absence (a) or presence of 0.032 lg/ml caspofungin (b) and (c). Scale bars represent
2 lm in (a) and (b) and 1 lm in (c). Light microscopy showing a Aspergillus
fumigatus hypha after 13 h (d) and 14 h (e) treatment with 2 lg/ml caspofungin, a
lysed tip is marked by the arrow. In (d) and (e) scale bar is equal to 10 lm.
Table 1
Selected cases of echinocandin therapy failure.
Clinical setting Pathogen Echinocandin therapy &
duration
CAS MIC (lg/
ml)
FKS1 mutation Reference
Oesophagitis (AIDS) C. albicans CAS (2 courses) >64 ND Hernandez et al. (2004)
Prosthetic aortic valve
endocarditis
C. parapsilosis CAS + FCZ for 6 weeks >16 ND Moudgal et al. (2005)
Disseminated (abdominal surgery) C. krusei CAS for 15 days 2 ND Pelletier et al. (2005)
Disseminated C. albicans CAS 4 S645F Park et al. (2005)
Candidaemia C. krusei CAS 32 R1361G Park et al. (2005)
Candidaemia C. glabrata CAS, AMB, VRC, >8 S633P Dodgson et al. (2005)
Azole refractory oesophagitis
(AIDS)
C. albicans CAS then MFG for total of
10 months
2 S645F,
R1361H
Laverdiere et al. (2006)
Recurrent oesophagitis (AIDS) C. albicans CAS, 2 courses with dose
escalation
8 S645P (homo) Miller et al. (2006)
Candidaemia (Acute Myeloid
Leukaemia)
C. krusei CAS for 17 days 8 F655C (Het) Hakki et al. (2006) and Kahn et al.
(2007)
Candidaemia C. glabrata CAS (3 courses) >16 ND Daneman et al. (2006)
Candidaemia C. parapsilosis CAS (+phenytoin) 0.25 ND Cheung et al. (2006)
Not reported C. glabrata Not reported 4 F659 V of Fks2 Katiyar et al. (2006)
Candidaemia C. glabrata VRC, CAS for 136 days >8 ND Krogh-Madsen et al. (2006)
Oesophagitis (AIDS) C. albicans CAS, 2 courses 2 F641S Baixench et al. (2007)
Oesophagitis (AML) C. tropicalis CAS 4 ND Pasquale et al. (2008)
Candidaemia C. glabrata CAS >4 D632E Cleary et al. (2008)
Candidaemia C. glabrata CAS for 61 days 8 F659 V of Fks2 Thompson III et al. (2008)
Candidaemia (HSCT) C. parapsilosis CAS for 41 days 1 ND Kabbara et al. (2008)
Candidaemia (HSCT) C. parapsilosis CAS for 50 days 1 ND Kabbara et al. (2008)
Candidaemia (HSCT) C.
guilliermondii
CAS for 26 days 0.5 ND Kabbara et al. (2008)
Candidaemia (AML) C. tropicalis CAS for 16 days 4 S645P (Het) Garcia-Effron et al. (2008b)
Candidaemia (HSCT) C. tropicalis CAS for 44 days 4 S645P (Het) Garcia-Effron et al. (2008b)
Candidaemia (cancer) C. tropicalis CAS for 21 days 1 F641L (homo) Garcia-Effron et al. (2008b)
Disseminated C. albicans CAS for 34 days 1 (>32 Etest) S645P Arendrup et al. (2009)
Not reported C. glabrataa CAS therapy or prophylaxis >2 Fks1,2a Garcia-Effron et al. (2009a)
a Twelve different clinical isolates reported with various Fks1, Fks2 point mutations.
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Although C. albicans is the most common cause of invasive
infections other Candida species are common agents of disease.
In a global surveillance of Candida species isolated from blood
and other sterile sites from 2001 to 2006 (n = 5, 346), 54% were
C. albicans followed by Candida parapsilosis (14%), C. glabrata
(14%), Candida tropicalis (12%), Candida krusei (3%) and C. guillier-
mondii (1%) (Pfaller et al., 2008a). The echinocandins are fungicidal
against the majority of pathogenic Candida species including iso-
lates, which are resistant to azole antifungals.
The minimum inhibitory concentration (MIC) of the echino-
candins to Candida spp. is determined using a standardised meth-
od which has been developed by the Clinical and Laboratory
Standards Institute (CLSI) Antifungal Subcommittee. The MIC
method uses RPMI-1640 as the test medium containing serial
dilutions of drug, which is subsequently inoculated with fungi
and incubated for 24 h at 35 C. The MIC can then be determined
by eye or by measuring optical density. The MIC is deﬁned as the
point at which there is a P50% inhibition of growth relative to
the control. The morphology of C. albicans yeast cells grown in
the presence of 0.032 lg/ml caspofungin, representing the typical
MIC, is shown in Fig. 2, a mixture of live and dead cells are pres-
ent (Fig. 2b) with some caspofungin-treated cells displaying wid-
ened mother-bud necks and septa (Fig. 2c). Recently the CLSI
Antifungal Subcommittee determined the MIC break point of sus-
ceptibility to the three echinocandins as 62 lg/ml for Candida
spp. (Pfaller et al., 2008b). However, this breakpoint may miss iso-
lates known to have caused breakthrough infections but which
have anidulafungin and micafungin MICs between 1 and 2 lg/
ml (Garcia-Effron et al., 2009a).
Different Candida species have different susceptibilities to
caspofungin. The susceptibility of Candida species to caspofunginranges from C. albicans as the most sensitive, then C. glabrata, C.
tropicalis and C. krusei with C. parapsilosis and C. guilliermondii
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2006; Pfaller et al., 2006b; Walker, Gow, Munro, unpublished). C.
parapsilosis and C. guilliermondii are thought to be intrinsically
more resistant to caspofungin due to naturally occurring point
mutations in Fks1 (Barchiesi et al., 2006; Canton et al., 2006; Gar-
cia-Effron et al., 2008a). All members of the C. parapsilosis family; C.
parapsilosis, Candida orthopsilosis and Candida metapsilosis contain a
point mutation at amino acid position 660 resulting in a proline to
alanine substitution, which is thought to make them intrinsically
less susceptible to caspofungin (Garcia-Effron et al., 2008a). Like-
wise, C. guilliermondii isolates contain three amino acid polymor-
phisms in the ﬁrst hot spot region, although only the methionine
to leucine substitution at position 642 is thought to be important
for reduced susceptibility to the echinocandins (Perlin, 2007).
Other intrinsically resistant fungal species such as Neurospora cras-
sa, Fusarium solani, Fusarium graminearum, Fusarium verticilliodes
and Magnaporthe grisea are known to contain a point mutation at
residue 641, in Fks1, which changes phenylalanine to tyrosine
(Ha et al., 2006; Katiyar et al., 2006). This suggests that point muta-
tions in Fks1 may lead to resistance to the echinocandins in a wide
range of fungal species. Likewise, C. guilliermondiiwas also found to
contain the same V641P substitution in Fks2 (Katiyar et al., 2006).
This may explain the intrinsic resistance of C. guilliermondii to the
echinocandins.4. Echinocandin resistance of Aspergillus species
The echinocandins have a largely fungistatic effect against
moulds and ﬁlamentous fungi such as species of Aspergillus. They
are cidal to the polarised, growing cell at the hyphal tip and can
lead to lysis of the hyphal tip, where the nascent cell wall is less
rigid due to the absence of cross-linking between glucan and chi-
tin. As treatment with the echinocandins fails to completely inhibit
growth in Aspergillus species, it is difﬁcult to determine a clear
point of inhibition and consequently an accurate MIC is hard to de-
ﬁne. As a result, an alternative method known as the minimum
effective concentration (MEC) has been introduced to determine
the activity of echinocandins against ﬁlamentous fungi. The MEC
is deﬁned as the lowest drug concentration at which short, stubby,
highly branched hyphae are observed (Arikan et al., 2001; Espinel-
Ingroff, 2003; Imhof et al., 2003; Kurtz et al., 1994; Odds et al.,
2004). Treatment of A. fumigatus with caspofungin leads to lysis
of hyphal tips (Fig. 2d and e). This lysis is a result of inhibition of
AfFks1, which is involved in synthesising new cell wall glucan at
the tips of hyphae (Beauvais et al., 2001; Bowman et al., 2002).
Although treatment with caspofungin results in lysis of hyphal tips,
viability staining has shown that older sub-apical compartments of
A. fumigatus hyphae are still viable after exposure to caspofungin
(Bowman et al., 2002).
As with the Candida species, different species of Aspergillus
have varying susceptibilities to echinocandins (Antachopoulos
et al., 2008; Imhof et al., 2003). Anidulafungin displays the great-
est inhibition of growth across the Aspergillus spp. compared to
caspofungin and micafungin. However, this differential inhibition
is negated when susceptibilities are tested in the presence of hu-
man serum, which is particularly relevant when testing the efﬁ-
cacy of IV drugs (Paderu et al., 2007). Generally A. fumigatus,
Aspergillus terreus and Aspergillus ﬂavus have comparable suscepti-
bilities to all three echinocandins (Antachopoulos et al., 2008). In
contrast Aspergillus niger has been shown to be considerably more
susceptible to caspofungin (MEC of 0.1–0.5 lg/ml) than A. fumig-
atus (MEC of 0.2–6 lg/ml), which is thought to be due to differ-
ences in cell wall composition (Imhof et al., 2003). Potential
mechanisms of resistance to caspofungin in A. fumigatus were
highlighted by two classes of laboratory generated mutants withreduced susceptibility to caspofungin (Gardiner et al., 2005).
Insertion of a point mutation within the AfFKS1 gene to generate
a S678Y amino acid substitution resulted in an MEC of 4 lg/ml
(Gardiner et al., 2005) and introducing a S678P mutation raised
the MEC of caspofungin, anidulafungin and micafungin to
>16 lg/ml (Rocha et al., 2007), compared to 0.25 lg/ml with the
susceptible wild-type strain. Spontaneous caspofungin resistant
mutants that were generated by cell wall digestion also displayed
reduced sensitivity to the drug independent of alterations in the
AfFKS1 sequence (Gardiner et al., 2005). Expression proﬁling of
these mutants after treatment with caspofungin showed upregu-
lation of genes involved in cell wall biosynthesis/remodelling,
structural cell components and transport (Gardiner et al., 2005).
Alternatively, a clinical isolate of A. fumigatus from a patient
who failed caspofungin therapy was resistant due to over-expres-
sion of the AfFKS1 gene (Arendrup et al., 2008). Furthermore,
Wetzstein et al., 2007 have reported the emergence of anidulafun-
gin-resistant moulds in two patients.5. Breakthrough infections
Global and nation-wide surveillance projects that have moni-
tored the echinocandin susceptibility of Candida spp. isolates, col-
lected since the introduction of this class of drugs into the clinic
in 2001, have not observed any emerging trends of resistance
(Cuenca-Estrella et al., 2006; Dannaoui et al., 2008; Pfaller et al.,
2006a, 2008a). However, since 2005 there have been several case
reports published that document failure of caspofungin therapy
(Table 1). In general, resistance to one echinocandin confers resis-
tance to all others with MICs of resistant isolates ranging from
1 lg/ml or above. Cross-resistance to polyenes or azoles was not
observed and some cases responded positively to subsequent
treatment with amphotericin B, or an azole or a combination of
both (Pelletier et al., 2005; Prabhu and Orenstein, 2004). The
underlying clinical settings in the breakthrough infections range
from AIDS to acute myeloid leukaemia and the type of infections
reported include oesophagitis, candidaemia and disseminated dis-
ease. Candida species which have demonstrated resistance to the
echinocandins include C. albicans, C. glabrata, C. parapsilosis, C.
krusei, C. guilliermondii and C. tropicalis. In a number of the studies
the gene encoding the echinocandin target Fks1 or the alternative
Fks2 glucan synthase sub-unit was sequenced and found to con-
tain at least one mutated allele. Risk factors associated with clin-
ical failure include prolonged therapy (Thompson III et al., 2008),
in several cases caspofungin had been administered for a long
period >15 days (Table 1). The bioavailability of the echinocandins
in some niches in the body has also been questioned, for example
vitreous penetration (Gauthier et al., 2005) and in the brain
(Pelletier et al., 2005). There are also reports of echinocandin
resistant moulds with two case reports of patients with haemato-
logical malignancies failing to respond to anidulafungin treatment
for proven and suspected aspergillosis (Wetzstein et al., 2007).
The FKS gene sequences of these resistant moulds have not been
reported. In another report of a double C. albicans/A. fumigatus
breakthrough infection the FKS1 gene of the resistant A. fumigatus
isolate did not contain any mutations (Arendrup et al., 2009). An-
other caspofungin resistant A. fumigatus isolate was also shown to
have a wild-type FKS1 gene but had altered expression of FKS1
highlighting another possible resistance mechanism (Arendrup
et al., 2008).6. Echinocandin paradoxical growth
In vitro studies that test the susceptibility of clinical fungal iso-
lates to echinocandins have reported a phenomenon termed the
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these studies echinocandins inhibited growth of C. albicans at low
concentrations but at concentrations from 8–32 lg/ml some
growth was observed and at even higher concentrations growth
inhibition was achieved again (Stevens et al., 2004, 2006; Wieder-
hold et al., 2005). This paradoxical growth at supra MICs differs
from the trailing growth phenomena observed in some clinical iso-
lates that are capable of persistent but reduced growth at higher
drug concentrations (Jacobsen et al., 2007).
The echinocandin paradoxical growth effect varies between
Candida species. Paradoxical growth occurs most frequently during
caspofungin treatment and is most prominent in clinical isolates of
C. parapsilosis, C. albicans, Candida dubliniensis, C. tropicalis and
occasionally with C. krusei (Chamilos et al., 2007; Fleischhacker
et al., 2008; Stevens et al., 2004). Paradoxical growth was only ob-
served in C. tropicalis and C. krusei with micafungin and in C. albi-
cans and C. tropicalis with anidulafungin. Paradoxical growth was
not observed when isolates of C. glabrata were treated with the
echinocandins (Chamilos et al., 2007). This suggests that some Can-
dida species are better able to adapt to cell wall damage caused by
the echinocandins. Interestingly, paradoxical growth was observed
more often with C. dubliniensis than with C. albicans and more fre-
quently with caspofungin over anidulafungin and micafungin (Fle-
ischhacker et al., 2008; Jacobsen et al., 2007). Using the CLSI M27-A
method Fleischhacker et al. (2008) were unable to detect any par-
adoxical growth in the presence of high concentrations of anidula-
fungin in either species. Paradoxical growth was also detected by
the EUCAST method for some clinical isolates but not by the CLSI
M27-Amethod (Jacobsen et al., 2007). These studies and the inabil-
ity to reproducibly demonstrate that the paradoxical growth effect
occurs in vivo have raised the question whether this phenomenon
is an artifact of in vitro growth (Jacobsen et al., 2007; Wiederhold,
2009). To date there is no clinical evidence that paradoxical growth
contributes to resistance or breakthrough infections.
It remains to be determined whether activation of chitin syn-
thesis or paradoxical growth could result in an alternative mecha-
nism of resistance to caspofungin in vivo. In one study four clinical
isolates of C. albicans, which showed the paradoxical effect in vitro
were subsequently tested in vivo to determine whether the same
pattern of re-growth was observed (Clemons et al., 2006). By deter-
mining CFU from the kidneys of infected mice, caspofungin was
found to be efﬁcacious against three of the four clinical isolates
(Clemons et al., 2006). The fourth isolate appeared to show para-
doxical growth in vivo, as it was able to survive better at 20 mg/
kg caspofungin than 5 mg/kg caspofungin, although this result
could not be reproduced in a subsequent experiment (Clemons
et al., 2006).
In contrast there is some evidence to suggest that paradoxical
growth occurs in vivo when A. fumigatus is treated with an echino-
candin drug. For example, in a rabbit model of invasive pulmonary
aspergillosis, pulmonary infarct scores did not differ between con-
trol animals and animals treated with caspofungin at 3 and 6 mg/
kg/day, although there was a reduction at 1 mg/kg/day (Petraitiene
et al., 2002). Likewise in the same model of infection, lungs from
animals treated with up to 2 mg/kg/day of micafungin showed
no difference in lung weight, displayed a hyphal fragmentation
pattern that was dose-dependent and resulted in increased pul-
monary fungal burden compared to the untreated control (Petraitis
et al., 2002). In another study that measured fungal burden using
quantitative real-time PCR, signs of paradoxical growth were de-
tected in a murine model of invasive pulmonary aspergillosis in re-
sponse to caspofungin treatment (Wiederhold et al., 2004).
Likewise, a murine model of central nervous system aspergillosis
demonstrated that treatment with micafungin at 5 mg/kg/day re-
sulted in signiﬁcant clearance of fungal burden from kidneys, com-
pared to the infected control. In contrast, treatment withmicafungin at 10 mg/kg/day did not signiﬁcantly clear fungal bur-
den from infected kidneys compared to the control (Clemons et al.,
2005). Paradoxical growth was also demonstrated in a neutropenic
rabbit model of invasive pulmonary aspergillosis treated with ani-
dulafungin. In this case lung weights of animals treated with 10
and 20 mg/kg/day did not differ signiﬁcantly in weight from lungs
of the control (Petraitis et al., 1998). It is worth noting that in the
cases mentioned above evidence of paradoxical growth did not re-
sult in increased mortality. Although, in one instance treatment
with 20 mg/kg/day micafungin, in a murine model of invasive pul-
monary aspergillosis, resulted in a higher mortality rate and in-
creased fungal burden. In contrast animals treated with 10 mg/
kg/day micafungin showed increased survival (Lewis et al., 2008).7. Bioﬁlms
Treatment of systemic, invasive Candida infections is often com-
plicated by the ability of Candida spp. to form bioﬁlms that are re-
calcitrant to azole antifungal drugs. As a fungal bioﬁlm develops
and matures extracellular matrix is produced that may act as a
physical barrier, protecting the underlying cells and binding anti-
fungal drugs hence lowering the available drug concentration
(d’Enfert, 2009). The bioﬁlm extracellular matrix remains poorly
characterised but there is evidence that b-(1,3)-glucan is a major
component (Al Fattani and Douglas, 2006; Nett et al., 2007). This
may be why echinocandins have been shown to be effective
against bioﬁlms (Katragkou et al., 2008; Kuhn et al., 2002; Ramage
et al., 2001). Furthermore the echinocandins are apparently not
substrates for the drug efﬂux pumps that can be upregulated when
C. albicans grows as a bioﬁlm (Andes et al., 2004; Mukherjee et al.,
2003; Ramage et al., 2002). Upregulation of efﬂux pumps is a well
established mechanism of azole resistance (Sanglard and Odds,
2002). The paradoxical growth observed in planktonic cells has
also been seen when cells are grown as bioﬁlms in vitro for C. albi-
cans, C. tropicalis, C. parapsilosis, C. metapsilosis and C. orthopsilosis
(Ferreira et al., 2009; Melo et al., 2007).8. Genome-wide screens to identify genes regulated by or
involved in the echinocandin response
A number of genome-wide approaches have been applied to
study the response of fungal cells to the echinocandin drugs and
to identify genes required for adaptive growth in the presence of
sub-lethal concentrations of echinocandins. Transcript proﬁling
of cells challenged with sub-MIC concentrations of caspofungin
using DNA microarrays have highlighted the genes that are acti-
vated in response to echinocandins in S. cerevisiae, A. niger and C.
albicans (Agarwal et al., 2003; Bruno et al., 2006; Liu et al., 2005;
Markovich et al., 2004; Meyer et al., 2007; Rauceo et al., 2008). In-
cluded in the upregulated genes are those that are a typical signa-
ture of activation of the PKC integrity pathway. Indeed this
signalling pathway is a major player in the response to echinocan-
dins, indicated by detection of the phosphorylated form of the PKC
pathway MAP kinase, Slt2/Mpk1 in S. cerevisiae, and Mkc1 in C.
albicans in response to caspofungin treatment (Reinoso-Martin
et al., 2003; Walker et al., 2008). In addition the mkc1D mutant
of C. albicans is hypersensitive to caspofungin and does not display
the paradoxical growth phenotype in vitro (Walker et al., 2008;
Wiederhold et al., 2005).
A screen of C. albicans transcription factor mutants for altered
susceptibility to caspofungin identiﬁed a novel protein Cas5 as
important for the response to echinocandins and a number of
caspofungin responsive genes are regulated by Cas5 (Bruno et al.,
2006). In addition, Sko1, a transcription factor downstream of the
HOG signalling pathway plays a role in the response to caspofungin
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screen of kinase mutants identiﬁed the Psk1 kinase as activating
Sko1 in response to caspofungin treatment in a novel signalling
pathway (Rauceo et al., 2008).
In C. albicans a ﬁtness screen of nearly 3000 heterozygous mu-
tants lacking one copy of each gene, termed a haploinsufﬁciency
screen, was used to investigate the mode of action of novel com-
pounds with potential antifungal activity (Xu et al., 2007). As a
proof of concept antifungal drugs with known modes of action,
including caspofungin, were also tested. Heterozygous mutants of
the b-(1,3)-glucan synthase sub-unit Fks1 and its regulatory sub-
unit Rho1 displayed haploinsufﬁciency, i.e. reduced ﬁtness upon
caspofungin treatment.9. Cell wall remodelling and impact of echinocandin-treatment
on the immune response
b-(1,3)-glucan is a hallmark component of nearly all fungi. It is
not surprising therefore that the human immune system has
evolved pattern recognition receptors to b-glucan that signal the
presence of a possible invasive fungus and elicit signalling events
leading to the induction of the innate immune response. Dectin-1
is a C-type lectin that is expressed in monocytes/macrophages,
neutrophils and dendritic cells, which recognises b-(1,3)-glucan
of fungal cell walls, plants and some ligands on mycobacterial cells
(Netea et al., 2008; Reid et al., 2009; Taylor et al., 2007; van de
Veerdonk et al., 2008). Dectin-1 mediated recognition often in-
volves the cooperative binding with other ligands via receptor
complexes – most notably TLR2. Binding of b-(1,3)-glucan induces
a wide range of responses including the synthesis of cytokines and
chemokines and dendritic cell maturation (Reid et al., 2009). As
b-(1,3)-glucan is a powerful inducer of the inﬂammatory innate
immune response it has been argued that the role of some of the
superﬁcial cell wall layers is to act as a protective barrier to pre-
vent immune cell recognition (Rappleye et al., 2007; Rappleye
and Goldman, 2008; Wheeler and Fink, 2006). Because echinocan-
dins have the potential to alter the amount and integrity of both
b-(1,3)-glucan and the cell wall, they also have the potential of
inﬂuencing the immune response to fungi (Ben Ami et al., 2008).
It has been observed that echinocandin-treatment can unmask
b-glucan in the deep layers of the cell wall. Unmasking has been
demonstrated by showing that impermeable molecules such as
the dectin-1-receptor or anti-b-glucan antibody can bind echino-
candin-treated cells (Wheeler et al., 2008). Echinocandin-treat-
ment can lead to enhanced killing of fungal cells by phagocytes
and alterations in cytokine production by immune cells encounter-
ing echinocandin-treated fungi (Chiller et al., 2001; Hohl et al.,
2008; Lamaris et al., 2008; Wheeler and Fink, 2006). For example,
caspofungin treatment was shown to enhance neutrophil killing of
hyphae of A. fumigatus, Rhizopus oryzae, Fusarium oxysporum and
Scedosporium species (Lamaris et al., 2008). Caspofungin or mica-
fungin treatment of conidia and germlings of A. fumigatus led to
a reduction in b-(1,3)-glucan levels and reduced synthesis of TNF
and CXL2 by macrophages. In contrast, macrophages that were ex-
posed to echinocandin-treated hyphae generated an enhanced
cytokine response and had increased b-glucan exposure (Hohl
et al., 2008). Hyphae, and not yeast cells, of C. albicans are prefer-
entially unmasked by caspofungin treatment in vivo (Wheeler
et al., 2008).
Therefore echinocandin exposure can cause numerous altera-
tions in the immune response – often enhancing dectin-1 mediated
and opsonic recognition of fungal cells, increasing the inﬂamma-
tory response and inducing more efﬁcient killing by lymphoid
cells. The underlying mechanisms are not completely clear. Some
of these effects may relate to the general perturbation in cell wallstructure and more efﬁcient dectin-1 mediated recognition of b-
glucan. Echinocandins may also reduce b-glucan content of the cell
wall even when dectin-1 mediated recognition is apparently
enhanced.10. Induction of chitin biosynthesis by cell wall salvage
pathways and the potential of combination therapies
The fungal cell wall is a dynamic structure and preventing the
synthesis of one component of the cell wall is known to lead to a
compensatory increase in another. Consequently, inhibition of
b-(1,3)-glucan synthesis by caspofungin results in a compensatory
increase in chitin synthesis in C. albicans (Fig. 3) (Walker et al.,
2008). This activation of chitin synthesis is mediated by the PKC,
Ca2+–calcineurin and HOG signalling pathways (Munro et al.,
2007). Furthermore, treating cells with activators of the PKC and
Ca2+–calcineurin pathways (Calcoﬂuor White and Ca2+) elevates
chitin content and reduces susceptibility to caspofungin in C. albi-
cans and A. fumigatus (Walker et al., 2008; Walker, Munro, Gow,
unpublished). Similarly, C. albicans cell wall mutants with elevated
chitin contents are less susceptible to caspofungin (Plaine et al.,
2008). At high concentrations of caspofungin C. albicans can form
resistant colonies, which have a signiﬁcantly higher chitin content
than susceptible, wild-type cells. This may constitute a form of
drug tolerance and appears to be an adaptive response as sub-cul-
turing these resistant cells in the absence of caspofungin resulted
in the chitin content returning to wild-type levels (Walker et al.,
2008). This suggests that C. albicans has the natural ability to adapt
to caspofungin treatment through a compensatory elevation of chi-
tin content.
The elevated chitin response is not speciﬁc to C. albicans as clin-
ical isolates of C. tropicalis, C. parapsilosis, C. guilliermondii and A.
fumigatus also show an increase in chitin content in response to
treatment with caspofungin (Fortwendel et al., 2009; Walker,
Gow, Munro, unpublished). Furthermore these species display
the highest incidence of in vitro paradoxical growth, in response
to caspofungin treatment (Antachopoulos et al., 2008; Chamilos
et al., 2007). In contrast, isolates of C. glabrata and C. krusei demon-
strate little or no occurrence of paradoxical growth and conse-
quently no increase in chitin content was observed after
treatment with caspofungin in these species (Chamilos et al.,
2007; Walker, Gow, Munro, unpublished). However, increased
SLT2 expression and chitin content have been associated with
incomplete killing of C. glabrata by caspofungin (Cota et al.,
2008). Therefore, elevation of chitin content in response to caspo-
fungin treatment is a good indication of which species are prone to
paradoxical growth. Interestingly isolates of different Candida spe-
cies that have point mutations in the Fks1 hot spot regions, render-
ing them resistant to caspofungin, do not show a compensatory
increase in chitin content in response to caspofungin treatment
(Walker, Gow, Munro, unpublished). Instead, isolates with point
mutations in Fks1 often contain a higher basal chitin content com-
pared to isolates with wild-type Fks1 (Walker, Gow, Munro,
unpublished).
Candida species and A. fumigatus demonstrate a compensatory
increase in chitin content in response to caspofungin treatment
highlighting the potential of combining chitin synthase inhibitors
with the echinocandins for improved and/or broader spectrum
therapy. Likewise, the response to caspofungin in C. albicans and
A. fumigatus, and the paradoxical growth that may be observed,
have been shown to involve the PKC, Ca2+–calcineurin and HOG
signalling pathways (Cota et al., 2008; Fortwendel et al., 2009;
Kelly et al., 2009; Walker et al., 2008; Wiederhold et al., 2005).
Consequently, inhibitors of these pathways may also act synergis-
tically with caspofungin. Recently the Cap1 signalling pathway has
Fig. 3. Treatment with caspofungin increases chitin content in C. albicans. (A) Transmission electron micrographs showing WGA-colloidal gold staining of chitin in wild-type
C. albicans (i) and after treatment with a sub-MIC concentration (0.032 lg/ml) of caspofungin (ii). (B) CFW staining was used to assess chitin levels of cells grown in YPD alone
(i), after treatment with 0.032 lg/ml caspofungin (ii), in YPD with 200 mM CaCl2 and 100 lg/ml CFW (iii) and after pre-growth with CaCl2 and CFW followed by exposure to
0.032 lg/ml caspofungin (iv). DIC images (top panels) and CFW ﬂuorescent images (bottom panels). Scale bars are (A) 0.2 lm and (B) 2 lm.
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ment in C. albicans (Kelly et al., 2009).
Chitin synthase inhibitors have been shown to enhance the
activity of caspofungin against C. albicans and A. fumigatus (San-
dovsky-Losica et al., 2008; Steinbach et al., 2007a; Walker et al.,
2008). This is an echinocandin wide effect as nikkomycin Z also en-
hances the activity of micafungin against A. fumigatus (Ganesan
et al., 2004). Similarly, anidulafungin shows synergy with nikko-
mycin Z against clinical isolates of A. fumigatus, C. albicans, Rhizopus
spp. and Coccidioides immitis (Stevens, 2000). Combination treat-
ment with chitin inhibitors and the echinocandins would be partic-
ularly beneﬁcial in the treatment of isolates which have intrinsic
resistance to the echinocandins. For example, the echinocandins
typically display fungistatic activity against A. fumigatus. In con-
trast, combination treatment of A. fumigatus with nikkomycin Z
and the echinocandins leads to synergistic killing through forma-
tion of extremely swollen spores with aberrant walls which are
prone to lysing (Chiou et al., 2001; Fortwendel et al., 2009; Stein-
bach et al., 2007a; Walker, Munro, Gow, unpublished). Further-
more, growth of a C. albicans strain, which was resistant to
caspofungin due to homozygous point mutations in CaFks1, could
be inhibited by combined treatment with caspofungin and several
different chitin inhibitors (Walker et al., 2008). Reﬂecting the
in vitro results, treatment with micafungin signiﬁcantly prolonged
survival when used in combination with nikkomycin Z against pul-
monary and systemic murine aspergillosis (Clemons and Stevens,
2006; Luque et al., 2003). Currently there are no chitin inhibitors,which are approved for clinical use, although there is obvious po-
tential for combination therapy with the echinocandins and chitin
inhibitors.
A blockade of the calcineurin pathway, through disruption of
genes or by use of calcineurin inhibitors, has also been shown to
act synergistically with caspofungin against C. albicans, A. fumigatus
and C. neoformans, in vitro (Del Poeta et al., 2000; Fortwendel et al.,
2009; Kontoyiannis et al., 2003; Kraus and Heitman, 2003; Stein-
bach et al., 2007a; Walker et al., 2008). Combined treatment of C.
albicans with caspofungin and the calcineurin inhibitor, cyclospor-
ine, also prevented the paradoxical growth seen at high concentra-
tions of caspofungin (Wiederhold et al., 2005).
Other potential mechanisms have been implicated in resistance
to the different classes of antifungal drugs but have been best stud-
ied with the azoles (Sanglard and Odds, 2002). Azole resistance can
be conferred by altering the drug target, Erg11, by changing Erg11
expression levels through a variety of mechanisms or upregulation
of efﬂux pumps, Mdr1, Cdr1 and Cdr2. In comparison resistance to
echinocandins is acquired by altering its target but there is little
evidence so far to suggest that the other mechanisms are occur-
ring. The role of Cdr1 and Cdr2 in echinocandin susceptibility re-
mains under debate (Niimi et al., 2006; Schuetzer-Muehlbauer
et al., 2003). Altered expression of the echinocandin target in re-
sponse to drug has not been studied in detail. However, C. glabrata
clinical isolates with hot spot mutations in Fks1 had elevated FKS1
expression (Garcia-Effron et al., 2009a) suggesting this mechanism
may also be occurring in at least some resistant isolates.
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Echinocandins are an important new generation of antifungal
agent whose mode of action is to bind to Fks1 leading to reduced
b-(1,3)-glucan synthesis resulting in damage to the integrity of
the cell wall. Clinical resistance to this class of agent is rare,
although point mutations in Fks1 in a range of species of fungi have
been found to confer resistance to echinocandins that can result in
clinical failures. In addition exposure to echinocandins induces a
salvage mechanism involving the upregulation of chitin synthesis.
This physiological adaptation enables a fungus to survive at other-
wise lethal concentrations of echinocandin and can be described as
a tolerance mechanism. Recently discovered mechanisms of resis-
tance to echinocandins also point the way to opportunities to en-
hance the efﬁcacy of this class of drug via combination therapies
that prevent these salvage mechanisms coming into operation. In
addition, perturbation of b-glucan synthesis in fungi leads to en-
hanced killing by phagocytes of the lymphoid cells of the immune
system and alterations in cytokine production – probably by
unmasking b-(1,3)-glucan that is normally buried in the internal
layers of the cell wall.
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